Cita APA

Ferrer Soler, L., Vázquez Martín, A., Brunet i Vidal, J., Menéndez Menéndez, J. A., Llorens Duran, R. d., & Colomer, R. (2007). An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressatrade mark)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

Citación estilo Chicago

Ferrer Soler, Laura, Alejandro Vázquez Martín, Joan Brunet i Vidal, Javier Abel Menéndez Menéndez, Rafael de Llorens Duran, y Ramon Colomer. An Update of the Mechanisms of Resistance to EGFR-tyrosine Kinase Inhibitors in Breast Cancer: Gefitinib (Iressatrade Mark)-induced Changes in the Expression and Nucleo-cytoplasmic Trafficking of HER-ligands (Review). 2007.

Cita MLA

Ferrer Soler, Laura, et al. An Update of the Mechanisms of Resistance to EGFR-tyrosine Kinase Inhibitors in Breast Cancer: Gefitinib (Iressatrade Mark)-induced Changes in the Expression and Nucleo-cytoplasmic Trafficking of HER-ligands (Review). 2007.